Citations

Showing 10 of 108152 citations.

COMPARISON OF CLINICAL SCORING SYSTEMS IN AGGRESSIVE B‐CELL LYMPHOMAS (BCL): AN INDIVIDUAL PATIENT‐LEVEL ANALYSIS ACROSS INTERNATIONAL TRIAL
Schmitz, Norbert , Wall, Anna, Poeschel, Viola, Tilly, Hervé , Ghesquières, Hervé , Ziepert, Marita , Flament, Jocelyne, Flowers, Christopher R. , Shi, Q., Ruppert, A. S., Dixon, Jesse G. , Salles, Gilles , Cunningham, David , Haïoun, Corinne , Shi, Q.

Mayo Clinic

Hematological Oncology | June 12, 2019 | Volume: 37 | Issue: S2 | Pages: 248-248

10.1002/hon.57_2630 Get It

THE CLINICAL COURSE OF DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) OVER TIME: A MULTISTATE SURVIVAL ANALYSIS USING META‐DATA FROM 13 FIRST‐LINE RANDOMIZED TRIALS
Çağlayan, Çağlar , Wall, Anna, Schmitz, Norbert , Poeschel, Viola, Seymour, John F. , Jaeger, Ulrich, Tilly, Hervé , Ghesiquieres, H., Ziepert, Marita , Flament, Jocelyne, Shi, Q., Flowers, Christopher R. , Dixon, Jesse G. , Salles, Gilles , Cunningham, David , Habermann, Thomas M. , Merli, Francesco , Haïoun, Corinne , Shi, Q.

Mayo Clinic

Hematological Oncology | June 12, 2019 | Volume: 37 | Issue: S2 | Pages: 247-248

10.1002/hon.56_2630 Get It

HEALTH‐RELATED QUALITY OF LIFE (HRQoL) IN RELAPSED/REFRACTORY (R/R) INDOLENT NHL IN THE PHASE 3 AUGMENT TRIAL OF RITUXIMAB (R) PLUS LENALIDOMIDE (R2) VERSUS R PLUS PLACEBO
Leonard, John P. , Fowler, Nathan , Zhang, H., Offner, Fritz , Scheliga, Adriana , Nowakowski, Grzegorz S. , Fogliatto, Laura , Moreira, Claudia Marcela Barrreiro, Tabah, Ashley , Abouzaid, Safiya, Kalambakas, Stacey, Wu, Chengqing , Trněný, Marek , Izutsu, Koji , Hong, X., Pinto, Antonio , Re, F., Scheinberg, Phillip , Flinn, Ian W. , Moreira, C., Fustier, Pierre , Gribben, John G.

Mayo Clinic

Hematological Oncology | June 12, 2019 | Volume: 37 | Issue: S2 | Pages: 232-234

10.1002/hon.45_2630 Get It

OUTCOMES AFTER EARLY TRANSFORMATION (tPOD24) VS. EARLY FOLLICULAR LYMPHOMA PROGRESSION (fPOD24) IN FOLLICULAR LYMPHOMA TREATED WITH FRONTLINE IMMUNOCHEMOTHERAPY
Jakopsen, L.H., Nowakowski, G. S., Ansell, Steven M., Thompson, Chester Andrew , Jørgensen, Judit , Frederiksen, Henrik , Novak, Anne J. , Frederiksen, Henrik , Maurer, Matthew J. , Habermann, Thomas M. , Brown, Peter de Nully , Syrbu, Sergei , Feldman, Andrew L. , Rimsza, Lisa M. , Cerhan, James R. , El‐Galaly, Tarec Christoffer , Link, Brian K.

Mayo Clinic

Hematological Oncology | June 12, 2019 | Volume: 37 | Issue: S2 | Pages: 231-232

10.1002/hon.44_2630 Get It

AUGMENT: RELAPSED/REFRACTORY INDOLENT NHL PATIENTS WERE MORE SENSITIVE TO NEXT TREATMENT FOLLOWING LENALIDOMIDE/RITUXIMAB (R2) THAN RITUXIMAB/PLACEBO
Fowler, Nathan , Zhang, H., Offner, Fritz , Scheliga, Adriana , Nowakowski, Grzegorz S. , Fogliatto, Laura Maria , Moreira, C. , Czuczman, M. S., Kalambakas, Stacey, Wu, Chengqing , Leonard, John P. , Gribben, John G. , Trněný, Marek , Izutsu, Koji , Hong, X., Pinto, Antonio , Re, F., Scheinberg, Phillip , Flinn, Ian W. , Fustier, Pierre

Mayo Clinic

Hematological Oncology | June 12, 2019 | Volume: 37 | Issue: S2 | Pages: 227-229

10.1002/hon.42_2630 Get It

POST HOC ANALYSES OF PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA WHO RECEIVED LENALIDOMIDE PLUS RITUXIMAB (R2) VS RITUXIMAB/PLACEBO (AUGMENT)
Thiéblemont, Catherine , Leonard, John P. , Fowler, Nathan , Zhang, H., Offner, Fritz , Scheliga, Adriana , Nowakowski, Grzegorz S. , Fogliatto, Laura , Moreira, C. , Czuczman, M. S., Kalambakas, Stacey, Wu, Chengqing , Gribben, JG, Trněný, Marek , Izutsu, Koji , Hong, X., Pinto, Antonio , Re, F., Scheinberg, Phillip , Flinn, Ian W. , Fustier, Pierre

Mayo Clinic

Hematological Oncology | June 12, 2019 | Volume: 37 | Issue: S2 | Pages: 226-227

10.1002/hon.41_2630 Get It

THE DIAL STUDY (DUAL IMMUNOMODULATION IN AGGRESSIVE LYMPHOMA): RANDOMIZED PHASE 2 TRIAL OF VARLILUMAB PLUS NIVOLUMAB IN RELAPSED/REFRACTORY AGGRESSIVE B‐CELL LYMPHOMAS
Reeder, Craig B. , LaPlant, Betsy, Adjei, Alex A. , Ansell, Stephen M. , Villasboas, José C. , Tun, Han W. , Bartlett, Nancy L. , Sharon, Elad

Mayo Clinic

Hematological Oncology | June 12, 2019 | Volume: 37 | Issue: S2 | Pages: 70-71

10.1002/hon.38_2629 Get It

PHASE III RANDOMIZED STUDY OF ENZASTAURIN/R‐CHOP VS PLACEBO/R‐CHOP IN FRONTLINE HIGH RISK DIFFUSE LARGE B CELL LYMPHOMA PATIENTS WITH GENOMIC BIOMARKER DGM1 (ENGINE STUDY)
Zhu, Jun , Smith, Stephen D. , O’Connor, Owen A. , Luo, Wen‐Lin, Shazer, Ronald , Zhang, L., Han, Isabel, Jivani, Manoj A., Liu, Y. , Nowakowski, Grzegorz S. , Song, Yuqin

Mayo Clinic

Hematological Oncology | June 12, 2019 | Volume: 37 | Issue: S2 | Pages: 70-70

10.1002/hon.37_2629 Get It

KIR3DL2 MUTATION MAY DEFINE A HIGH RATE OF RESPONSE OF AITL TO TIPIFARNIB
Scholz, Catherine, Mishra, Vishnu S. , Kessler, Linda , Rodríguez, Marta , Gualberto, Antonio , Piris, Miguel Á. , Witzig, Thomas E.

Mayo Clinic

Hematological Oncology | June 12, 2019 | Volume: 37 | Issue: S2 | Pages: 204-204

10.1002/hon.20_2630 Get It